BMPR2 and pulmonary arterial hypertension: The downregulation of miR-191 activates bone morphogenetic protein receptor 2 (BMPR2) mutations by preventing BMPR2 degradation, which inhibits exaggerated inflammatory responses, rescues age-related endothelial dysfunction, and reverses PAH [41, 96].